Table 7.
Active recruiting of clinical trials for treatment of meningioma, updated and modified from Al-Rashed (139).
| Drug (Trade Name) | Target | ClinicalTrials.gov Identifier |
|---|---|---|
| Immunotherapies | ||
| Pembrolizumab (Keytruda) | PD-1 | NCT03279692 NCT03016091 |
| Avelumab and Hypofractionated Proton Radiation Therapy | PD-1 | NCT03267836 |
| Nivolumab (Opdivo) with or without Ipilimumab (Yervoy) | PD-1 | NCT03604978 |
| Nivolumab (Opdivo) | PD-1 | NCT03173950 |
| Targeted small molecules | ||
| Vistusertib (AZD2014) | mTORC1/mTORC2 | NCT03071874 |
| Alpelisib (Piqray) and Trametinib (Mekinist) | PI3K/MEK | NCT03631953 |
| Ribociclib | cyclin D1/CDK4 & CDK6 | NCT02933736 |
| Brigatinib (Alunbrig) | NF2 | NCT04374305 |
| Selumetinib | NF2 | NCT03095248 |
| Abemaciclib | CDK4/6 | NCT03220646 |
| Peptide receptor radionuclide therapy (PRRT) | ||
| 177Lu-DOTATATE (Lutathera) | SSR | NCT03971461 NCT04082520 |
| Somatostatin receptor (SSTR) | ||
| SOM230C | pasireotide LAR | NCT00859040 |
| Tumor Treating Field | ||
| NovoTTF-110A (Optune) and Bevacizumab (Avastin) | N/A | NCT02847559 |